abrdn plc Boosts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

abrdn plc lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 380,535 shares of the medical device company's stock after buying an additional 66,348 shares during the quarter. abrdn plc owned about 0.10% of DexCom worth $47,221,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Valley National Advisers Inc. lifted its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after buying an additional 103 shares in the last quarter. MV Capital Management Inc. lifted its position in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock worth $34,000 after purchasing an additional 138 shares in the last quarter. Washington Trust Advisors Inc. lifted its position in shares of DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company's stock worth $44,000 after purchasing an additional 193 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in shares of DexCom in the fourth quarter worth $57,000. Finally, NBC Securities Inc. bought a new stake in shares of DexCom in the third quarter worth $47,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. UBS Group boosted their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a "buy" rating in a research report on Wednesday, April 10th. Raymond James boosted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 23rd. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Royal Bank of Canada began coverage on shares of DexCom in a report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 target price on the stock. Finally, StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $141.40.

DexCom Stock Performance

Shares of DXCM stock traded up $0.81 on Monday, hitting $131.52. The company's stock had a trading volume of 2,110,057 shares, compared to its average volume of 2,971,117. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a market capitalization of $50.70 billion, a PE ratio of 100.40, a PEG ratio of 2.25 and a beta of 1.20. The stock's 50 day moving average is $129.81 and its 200-day moving average is $117.38. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the firm earned $0.34 earnings per share. DexCom's revenue for the quarter was up 26.9% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company's stock, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.